Search results for "Juva"

showing 10 items of 739 documents

The Potential Role of Lung Ultrasound B-Lines for Detection of Lung Radio-Induced Toxicity in Breast Cancer Patients after Radiation Therapy.

2016

Breast cancer patients exposed to doses of radiation after radiotherapy could develop toxicity to lung. Lung ultrasound (LUS) is able to detect interstitial lung disease by the evaluation of B-lines. The aim of our study was to assess the number of B-lines to diagnose lung involvement after chest radiotherapy.We measured LUS B-lines in the treated and contralateral lung of 20 breast cancer patients, 1-3 months after the end of radiotherapy and 1 year after previous LUS. The sum of the B-lines number in the 72 sites on anterior and posterior chest yielded a global B-lines score.B-lines were more numerous in treated (median: 21; 1st-3rd quartiles: 11-31) versus untreated hemithorax (median: 3…

Adultmedicine.medical_specialtymedicine.medical_treatmentBreast Neoplasms030204 cardiovascular system & hematologySensitivity and Specificity03 medical and health sciences0302 clinical medicineBreast cancermedicineHumansRadiology Nuclear Medicine and imagingStage (cooking)Subclinical infectionUltrasonographyLungbusiness.industryInterstitial lung diseaseReproducibility of ResultsMiddle Agedmedicine.diseaseRadiation therapyRadiation Pneumonitismedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisToxicityBiomarker (medicine)Feasibility StudiesFemaleRadiotherapy AdjuvantRadiologyRadiotherapy ConformalCardiology and Cardiovascular MedicinebusinessEchocardiography (Mount Kisco, N.Y.)
researchProduct

Comorbidity-dependent adherence to guidelines and survival in breast cancer-Is there a role for guideline adherence in comorbid breast cancer patient…

2016

In the treatment of breast cancer, decisions on adjuvant treatment reflect individual patient characteristics like age and comorbidity. This study assessed the association between adherence to guidelines for adjuvant treatment and survival while taking into account age at diagnosis and comorbidities. We collected the Charlson comorbidity index at baseline for 2179 women treated for primary breast cancer from 1992 to 2008 who participated in a German retrospective multicenter cohort study. We assessed subsequent adjuvant therapy guideline adherence and survival in relation to baseline comorbidities. Guidelines for adjuvant chemotherapy and radiotherapy were more often violated in patients wi…

Adultmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsComorbidityKaplan-Meier EstimateDisease-Free Survival03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineOutcome Assessment Health CareInternal MedicinemedicineAdjuvant therapyHumans030212 general & internal medicineAgedProportional Hazards ModelsRetrospective StudiesAged 80 and overbusiness.industryHazard ratioAge FactorsRetrospective cohort studyGuidelineMiddle Agedmedicine.diseaseComorbiditySurgerySurvival RateOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisSurgeryFemaleGuideline AdherencebusinessMastectomyCohort studyFollow-Up StudiesThe breast journal
researchProduct

Minilaparoscopic aortic lymphadenectomy.

2015

Abstract Study Objective To show the feasibility of performing aortic lymphadenectomy with 3-mm instruments in gynecologic malignancies. Patient A 43-year-old, multiparous patient with serous ovarian cancer grading 2, Federation Internationale de Gynecologie et d'Obstetrique stage IC (intraoperative spillage). Intervention The patient was accidentally diagnosed with ovarian cancer after a right adnexectomy performed for an ovarian cyst. Once referred to our center, a delayed surgical staging was planned including total hysterectomy, left adnexectomy, aortic and pelvic lymphadenectomy, peritoneal biopsies, and total omentectomy. Minilaparoscopy was believed to be feasible to achieve it. Meas…

Adultmedicine.medical_specialtymedicine.medical_treatmentOperative TimeSerous ovarian cancermedicineHumansGynecologic cancerGrading (tumors)AortaOvarian NeoplasmsHysterectomyOvarian cystbusiness.industryOvarian NeoplasmMedicine (all)Lymph NodeObstetrics and GynecologyPostoperative complicationmedicine.diseaseSurgeryminilaparoscopicMinilaparoscopyFeasibility StudieSettore MED/40 - GINECOLOGIA E OSTETRICIATreatment OutcomeChemotherapy AdjuvantOperative timeFeasibility StudiesLymph Node ExcisionLymphadenectomyFemaleLaparoscopyLymph NodesNeoplasm Recurrence LocalOvarian cancerbusinessaortic lymphadenectomyHumanJournal of minimally invasive gynecology
researchProduct

How Technology Can Impact Surgeon Performance: A Randomized Trial Comparing 3-Dimensional versus 2-Dimensional Laparoscopy in Gynecology Oncology

2016

This randomized clinical trial (Canadian Task Force classification I) aimed to compare 2-dimension (2-D) versus 3-dimensional (3-D) laparoscopic hysterectomy and pelvic lymphadenectomy in endometrial and cervical cancer patients. Between December 2014 and March 2015, 90 patients were enrolled: 29 (32.2%) with early or locally advanced cervical cancer after neoadjuvant treatment and 61 (67.8%) with early-stage endometrial cancer. Patients were randomly assigned to undergo 2-D (Group A, n = 48 [53.3%]) or 3-D (Group B, n = 42 [46.7%)]) laparoscopy. Baseline characteristics were superimposable in the 2 groups. Median operative time was similar in the 2 groups. Median estimated blood loss durin…

Adultmedicine.medical_specialtymedicine.medical_treatmentOperative TimeUterine Cervical NeoplasmsHysterectomylaw.invention03 medical and health sciencesImaging Three-DimensionalPostoperative Complications0302 clinical medicineRandomized controlled trialEndometrial cancerlawThree-dimensional laparoscopicmedicineHumansLaparoscopyNeoadjuvant therapyCervical cancer; Endometrial cancer; Three-dimensional laparoscopicAgedSurgeonsGynecologyCervical cancerHysterectomymedicine.diagnostic_testbusiness.industryEndometrial cancerGeneral surgeryObstetrics and GynecologyPerioperativeMiddle Agedmedicine.diseaseNeoadjuvant TherapyEndometrial NeoplasmsSurgery030220 oncology & carcinogenesisCervical cancerLymph Node ExcisionFemaleLaparoscopy030211 gastroenterology & hepatologyLymphadenectomyClinical CompetenceCervical cancer; Endometrial cancer; Three-dimensional laparoscopic; Obstetrics and Gynecologybusiness
researchProduct

Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.

2007

Liver or lung metastases usually relapse under chemotherapy. Such life-threatening condition urgently needs new, systemic anticancer compounds, with original and efficient mechanisms of action. In B16 melanoma mice treated with cyclophosphamide, D'Agostini et al. [D'Agostini, C., Pica, F., Febbraro, G., Grelli, S., Chiavaroli, C., Garaci, E., 2005. Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions. Int. Immunopharmacol. 5, 1205-1212.] recently found that OM-174, a chemically defined Toll-like receptor(TLR)2/4 agonist, reduces tumor progression and prolongs survival. Here we review 149 articles concerning molecular mechanisms of TLR2…

AgonistLipopolysaccharidesCyclophosphamidemedicine.drug_classmedicine.medical_treatmentNitric Oxide Synthase Type IIAntineoplastic AgentsApoptosisNitric oxidechemistry.chemical_compoundRecurrenceNeoplasmsMedicineAnimalsHumansPharmacologyChemotherapybusiness.industryTumor Necrosis Factor-alphaCancerDendritic Cellsmedicine.diseaseNeoadjuvant TherapyToll-Like Receptor 2Interleukin-10Toll-Like Receptor 4TLR2Lipid ATreatment OutcomechemistryTumor progressionChemotherapy AdjuvantDrug Resistance NeoplasmEnzyme InductionImmunologyCancer researchBCG VaccineTumor necrosis factor alphaImmunotherapybusinessmedicine.drugSignal TransductionT-Lymphocytes CytotoxicEuropean journal of pharmacology
researchProduct

An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product f…

2012

Background Subcutaneous specific immunotherapy (SCIT) has proven sustained clinical efficacy against allergy. The recommended regimen for SCIT is a gradual updosing over a period of weeks. Commonly, in commercial products for SCIT, the specific allergen is formulated with an adjuvant, most often in the form of aluminium hydroxide (AlOH). It has been shown that allergen-specific IgG antibodies are induced as a result of successful SIT. Objective To investigate the possibility of optimizing the formulation of AlOH-based grass-pollen allergy vaccines for SCIT in a way that allows for shorter updosing regimens while maintaining the immunogenicity of the vaccine. Methods Mice were immunized with…

AllergyInjections SubcutaneousT-LymphocytesT cellmedicine.medical_treatmentImmunologyAluminum HydroxidePharmacologyPoaceaemedicine.disease_causePhleumMiceAllergenAdjuvants ImmunologicAnimalsHumansImmunology and AllergyMedicineMice Inbred BALB CbiologyPlant Extractsbusiness.industryImmunogenicityRhinitis Allergic SeasonalAllergen extractAllergensmedicine.diseasebiology.organism_classificationTreatment Outcomemedicine.anatomical_structureDesensitization ImmunologicImmunoglobulin GPhleumImmunologybiology.proteinPollenFemaleAntibodybusinessAdjuvantClinical & Experimental Allergy
researchProduct

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

2013

Carbon nanotubes (CNTs) are nanomaterials with interesting emerging applications. Their properties make CNTs excellent candidates for use as new nanovehicles in drug delivery, immunization and diagnostics. In the current study, we assessed the immune-response-amplifying properties of CNTs to haptens by using azoxystrobin, the first developed strobilurin fungicide, asamodel analyte. Anazoxystrobin derivative bearingacarboxylated spacer arm (hapten AZc6) was covalently coupled to bovine serum albumin (BSA), and the resulting BSA-AZc6 conjugate was covalently linked to four functionalized CNTs of different shapes and sizes, varying in diameter and length. These four types of CNT-based construc…

Analytemedicine.medical_treatmentAzoxystrobinFreund's AdjuvantAntigen deliveryCarbon nanotubesPharmaceutical ScienceAntibodiesBiomaterialsMicechemistry.chemical_compoundMicroscopy Electron TransmissionmedicineAnimalsOrganic chemistryBovine serum albuminDrug CarriersMice Inbred BALB CbiologyNanotubes CarbonChemistrySerum Albumin BovineStrobilurinsFungicides IndustrialPyrimidinesAzoxystrobinImmunoglobulin GDrug deliverybiology.proteinBiophysicsMethacrylatesFemaleImmunizationRabbitsAntibodyHaptensAdjuvantHaptenConjugate
researchProduct

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

2015

How dying tumor cells get noticed Besides killing tumor cells directly, some chemotherapies, such as anthracyclines, also activate the immune system to kill tumors. Vacchelli et al. discovered that in mice, anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1). Dendritic cells (DCs) near tumors expressed especially high amounts of FPR1. DCs normally capture fragments of dying tumor cells and use them to activate nearby T cells to kill tumors, but DCs lacking FPR1 failed to do this effectively. Individuals with breast or colon cancer expressing a variant of FPR1 and treated with anthracyclines showed poor metastasis-free and ov…

AnthracyclineColorectal cancermedicine.medical_treatmentT-LymphocytesBreast Neoplasmsmicrofluidic chipchemotherapyPolymorphism Single NucleotideFormyl peptide receptor 1immune responseMiceImmune systemImmunityCell Line TumorNeoplasmsmedicineLeukocytesAnimalsHumansAnthracyclinesAllelesAnnexin A1ChemotherapyMultidisciplinarybusiness.industryDendritic Cellsmedicine.diseaseReceptors Formyl PeptideImmunity InnateChemotherapy AdjuvantCancer cellImmunologyCancer researchFemalebusinessColorectal NeoplasmsAdjuvantFPR1 microfluidicScience (New York, N.Y.)
researchProduct

Zanhasaponins A and B, Antiphospholipase A2 Saponins from an Antiinflammatory Extract of Zanha africana Root Bark

1997

A MeOH extract from Z. africana was examined for topical antiinflammatory activity and proved to be active against arachidonic acid (AA) acute edema, 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced chronic inflammation, and oxazolone delayed-type hypersensitivity in mice. The extract also showed significant inhibitory activity of Naja naja phospholipase A2 when a polarographic method was used. Two oleanane-type triterpene saponins, zanhasaponins A (1) and B (2), and the cyclitol pinitol (4), isolated from the extract, were active as inhibitors of PLA2. A further saponin, zanhasaponin C (3) was inactive in this assay.

Anti-Inflammatory AgentsSaponinPharmaceutical SciencePharmacognosyDermatitis ContactPhospholipases AAnalytical ChemistryMicechemistry.chemical_compoundPhospholipase A2Adjuvants ImmunologicTriterpeneDrug DiscoveryAnimalsEdemaEnzyme InhibitorsPeroxidaseSkinPharmacologychemistry.chemical_classificationintegumentary systembiologyTraditional medicineOrganic ChemistryOxazoloneGlycosideSaponinsTriterpenesTerpenoidPhospholipases A2Complementary and alternative medicinechemistryBiochemistryvisual_artvisual_art.visual_art_mediumbiology.proteinTetradecanoylphorbol AcetateMolecular MedicineFemaleBarkArachidonic acidJournal of Natural Products
researchProduct

Cellular and humoral immune responses against cancer: implications for cancer vaccines.

1991

The key issue in tumor immunology is to identify antigens as target structures for a cancer-selective immunological attack in the tumor-bearing host, resulting in tumor rejection. There is a growing detailed understanding of structural and regulatory gene alterations giving rise to candidate rejection antigens and peptides in tumor cells. As well as reviewing the development of new adjuvant and recombinant vector systems, new approaches are suggested for the construction of cancer vaccines.

Antibodies Neoplasmmedicine.medical_treatmentImmunologyBiologyMajor histocompatibility complexMiceImmune systemAntigenAntigens NeoplasmGangliosidesNeoplasmsmedicineImmunology and AllergyAnimalsHumansVector (molecular biology)Immunity CellularLymphokinesVaccinesVaccines SyntheticCancerNeoplasms Experimentalmedicine.diseaseCTL*ImmunologyAntibody Formationbiology.proteinBCG VaccineCytokinesTumor necrosis factor alphaAdjuvantT-Lymphocytes CytotoxicCurrent opinion in immunology
researchProduct